Veranex, a concept-to-commercialisation global service provider dedicated to the medtech industry, has acquired IMMR, a preclinical science organisation that provides preclinical research, pathology evaluation and surgical training services to medical technology innovators.
Formed in June 2021 with global growth investor Summit Partners, Veranex provides the medical technology industry with integrated solutions and services that accelerate the product lifecycle to help improve the lives of patients. As a result of this acquisition, Veranex gains FDA-inspected and AAALAC-accredited facilities and in-house expertise.
Patrick K. Donnelly, executive chairman at Veranex, said: “We are excited to welcome the world-class and market leader IMMR to Veranex. Veranex is focussed on the needs of the medtech industry and this acquisition enhances our long-term ability to meet the end-to-end needs of medtech companies in one organisation. Veranex’s clients will benefit from IMMR’s 30-plus years of experience in the design and conduct of preclinical studies, expertise in complex cardiovascular and non-cardiovascular procedures, and state-of-the-art surgical suites and husbandry facilities, all unparalleled for leading successful completion of sophisticated studies with novel interventional or surgical technologies.”
IMMR founding partner and scientific director Luc Behr, D.V.M., Ph.D, added: “As part of a combined company with a full range of product development, regulatory, and market access expertise, our partnership with Veranex complements our vision to help clients achieve their objectives and advance important medtech innovations that significantly improve patient care. IMMR adds another dimension of expertise and services to Veranex to enable and accelerate research in the industry.”
Are you hiring?
